Core Viewpoint - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. has successfully completed nearly 400 million RMB financing to advance multiple innovative drugs into critical Phase III clinical trials and expand its R&D pipeline [1][3]. Group 1: Company Overview - Founded in 2019, Zeling Biopharmaceutical focuses on unmet medical needs, particularly in oncology, autoimmune diseases, inflammation, and neurological disorders, aiming to discover and commercialize First-in-Class (FIC) and Best-in-Class (BIC) innovative drugs [3][4]. - The company has established a comprehensive innovation platform covering the entire lifecycle of drug development, including AI molecular design, structural biology, high-throughput screening based on organoids, PDX model construction, CMC research, clinical strategy formulation, and new drug registration [3][4]. Group 2: Product Pipeline - Zeling Biopharmaceutical has developed 7 innovative products with international competitiveness, with one indication entering critical Phase III and five indications in Phase II clinical trials [4][5]. - The core product, Purinostat Mesylate (PM), is the world's first single-agent high-selectivity HDAC inhibitor for relapsed/refractory lymphoma, achieving an objective response rate (ORR) of 69.0% in Phase IIa studies, comparable to existing combination therapies [4][6]. - Another significant product, Flonoltinib Maleate (FM), shows promising efficacy as a FIC potential JAK2/FLT3/CDK6 inhibitor in myelofibrosis, with over 80% of patients achieving a ≥35% reduction in spleen volume [5][6]. Group 3: Technological Advancements - Zeling Biopharmaceutical has obtained 34 invention patents, including 17 international patents, with an additional 45 patents pending [6]. - The integration of structural biology, AI drug design, and organoid-PDX dual-track validation has created a unique end-to-end innovation engine for drug development, facilitating the rapid transition of novel drugs into clinical development [6][7]. Group 4: Future Outlook - The company aims to accelerate its international expansion, with 2025 projected as a pivotal year for global growth, as it seeks to enter overseas markets and establish a presence on the global stage for innovative drugs [7]. - Investors have shown strong confidence in the company's development strategy and research outcomes, highlighting the potential for Zeling Biopharmaceutical to emerge as a significant player in the global innovative drug market [7].